{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:43:39Z","timestamp":1765889019605,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clml.2022.12.004","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:53:50Z","timestamp":1670615630000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and\/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-4953","authenticated-orcid":false,"given":"B.R.","family":"Shank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-8363","authenticated-orcid":false,"given":"B.","family":"Primeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-3008","authenticated-orcid":false,"given":"E.K.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.B.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Roccograndi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.P.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0857-176X","authenticated-orcid":false,"given":"E.E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Becnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-7058","authenticated-orcid":false,"given":"S.K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.004_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.004_bib0002","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1002\/cncr.29533","article-title":"A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma","volume":"121","author":"Griffin","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.004_bib0003","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1016\/j.clml.2020.07.015","article-title":"Modified hyper-CVAD with proteasome inhibition for multiple myeloma: a single-center retrospective analysis","volume":"20","author":"Narayan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.004_bib0004","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jha2.275","article-title":"Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed\/refractory multiple myeloma with extramedullary disease","volume":"2","author":"Abdallah","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2022.12.004_bib0005","first-page":"41","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients","volume":"12","author":"Dadacaridou","year":"2007","journal-title":"J BUON"},{"key":"10.1016\/j.clml.2022.12.004_bib0006","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.004_bib0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.004_bib0008","first-page":"9097","article-title":"Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a salvage and bridging regimen before hematopoietic stem cell transplantation for relapsed or refractory multiple myeloma","author":"Togano","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.clml.2022.12.004_bib0009","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.004_bib0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.12.004_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2","article-title":"HyperCVAD for VAD-resistant multiple myeloma","volume":"52","author":"Dimopoulos","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.004_bib0012","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.12.004_bib0013","article-title":"Carfilzomib, cyclophosphamide and dexamethasone (KCD) versus bortezomib, cyclophosphamide and dexamethasone (VCD) for treatment of first relapse or primary refractory multiple myeloma (MM): first final analysis of the phase 2 muk five study","volume":"130","author":"Yong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.004_bib0014","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.12.004_bib0015","unstructured":"National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03. NIH publication 09-5410. Published May 29, 2009; Revised June 14, 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed December 30, 2021."},{"key":"10.1016\/j.clml.2022.12.004_bib0016","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.004_bib0017","unstructured":"NCCN. Guidelines multiple myeloma version 7. 2021. Accessed July 31, 2021. www.nccn.org"},{"key":"10.1016\/j.clml.2022.12.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.5377.5377","article-title":"VDTPACE as salvage therapy for heavily pretreated MM patients","volume":"122","author":"Buda","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.004_bib0019","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.clml.2017.10.008","article-title":"Modified HyperCVAD versus bortezomib-hyperCAD in patients with relapsed\/refractory multiple myeloma","volume":"18","author":"Saraceni","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.004_bib0020","article-title":"Use of KRD-PACE as salvage therapy in aggressive, relapsed\/bortezomib-refractory extramedullary multiple myeloma: a report of two cases and literature review","volume":"2020","author":"Parrondo","year":"2020","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2022.12.004_bib0021","unstructured":"Onyx Pharmaceuticals, Inc. Kyprolis (carfilzomib) package insert. Thousand Oaks, CA. 2021."},{"key":"10.1016\/j.clml.2022.12.004_bib0022","unstructured":"Janssen Biotech, Inc. Darzalex (daratumumab) package insert. Horsham, PA. 2021."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:25Z","timestamp":1761871285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2152265022017499"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and\/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}